Medtronic stock gains clinical support from ablation registries

Medtronic reported positive real-world registry results for two cardiac ablation systems on October 22, 2026, with the findings presented at the Asia Pacific Heart Rhythm Society meeting. The announcement covers the Affera Mapping and Ablation System with the Sphere-9 catheter and the PulseSelect pulsed field ablation system, according to Stifel company news.

Real-world evidence spans heart rhythms

The global prospective APEX registry included 1,050 patients with atrial fibrillation treated with Sphere-9 and Affera across 28 sites. Medtronic reported a 1.1 percent major complication rate and no cases of acute kidney injury, severe coronary spasm or phrenic nerve injury. Major complication rates did not differ significantly between first-time and repeat ablation procedures.

The REAL PULSE registry covered 1,160 atrial fibrillation patients treated with PulseSelect at 38 sites. The company reported a 100 percent acute procedural success rate and an acute major complication rate of 0.09 percent. These results add real-world evidence to a portfolio aimed at treating abnormal heart rhythms.

Ventricular data remain preliminary

A separate European APEX analysis examined Sphere-9 in 46 patients with sustained ventricular tachycardia. Acute procedural success reached 87 percent, while estimated freedom from ventricular tachycardia recurrence at six months stood at 75 percent. Six major complications occurred in four patients.

Medtronic said Sphere-9 is CE marked for ventricular tachycardia in applicable markets but remains investigational and is not approved for that indication in the United States. The small patient group and the limited follow-up make the ventricular findings an early clinical signal rather than revenue guidance.

Market context for Medtronic stock

Medtronic stock traded at 93.24 euros on Lang & Schwarz at 11:52 CET on Thursday, November 5, 2026. Investors may view the registry results as support for the company's electrophysiology strategy, although clinical evidence alone does not establish a change in near-term sales or earnings expectations.

For a live market view, see the real-time quote of Medtronic stock.

Broader conditions for US equities can be followed in the S&P 500 market environment.

Further updates will depend on additional clinical evidence, commercial adoption and Medtronic's next financial report. See More news and analyses on Medtronic stock.